Suppr超能文献

实验性中枢神经系统曲霉病治疗:疗效、药物水平和定位、免疫组织病理学和毒性。

Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

机构信息

California Institute for Medical Research, San Jose, California, USA.

出版信息

Antimicrob Agents Chemother. 2012 Aug;56(8):4439-49. doi: 10.1128/AAC.06015-11. Epub 2012 Jun 11.

Abstract

We have shown previously that high-dose lipid amphotericin preparations are not more efficacious than lower doses in aspergillosis. We studied toxicity, drug concentrations and localization, and quantitative infection concurrently, using a 4-day model of central nervous system (CNS) aspergillosis to assess early events. Mice given Aspergillus fumigatus conidia intracerebrally, under a cyclophosphamide immunosuppressive regimen, were treated for 3 days (AmBisome at 3 or 10 mg/kg of body weight, Abelcet at 10 mg/kg, amphotericin B deoxycholate at 1 mg/kg, caspofungin at 5 mg/kg, or voriconazole at 40 mg/kg). Sampling 24 h after the last treatment showed that AmBisome at 3 but not at 10 mg/kg, as well as Abelcet, caspofungin, and voriconazole, reduced brain CFU. All regimens reduced renal infection. Minor renal tubular changes occurred with AmBisome or Abelcet therapy, whereas heart, lung, and brain showed no drug toxicity. Amphotericin B tissue and serum concentrations did not correlate with efficacy. Endothelial cell activation (ICAM-1 and P-selectin in cerebral capillaries) occurred during infection. Amphotericin B derived from AmBisome and Abelcet localized in activated endothelium and from Abelcet in intravascular monocytes. In 10-day studies dosing uninfected mice, minor renal tubular changes occurred after AmBisome or Abelcet at 1, 5, or 10 mg/kg with or without cyclophosphamide treatment; nephrosis occurred only with Abelcet in cyclophosphamide-treated mice. Hepatotoxicity occurred with AmBisome and Abelcet but was reduced in cyclophosphamide-treated mice. Marked CFU reduction by AmBisome at 3 mg/kg occurred in association with relatively more intense inflammation. Abelcet renal localization appears to be a precursor to late nephrotoxicity. Hepatotoxicity may contribute to high-dose Abelcet and AmBisome failures. Our novel observation of endothelial amphotericin localization during infection may contribute to amphotericin mechanism of efficacy.

摘要

我们之前已经表明,高剂量脂质两性霉素制剂在曲霉菌病中的疗效并不优于低剂量制剂。我们使用中枢神经系统(CNS)曲霉菌病的 4 天模型,同时研究了毒性、药物浓度和定位以及定量感染,以评估早期事件。在环磷酰胺免疫抑制方案下,将烟曲霉分生孢子脑内给药的小鼠,用 3 天治疗(两性霉素 B 脂质体 3 或 10mg/kg 体重,两性霉素 B 去氧胆酸盐 1mg/kg,阿比可尔 10mg/kg,卡泊芬净 5mg/kg,伏立康唑 40mg/kg)。最后一次治疗后 24 小时采样显示,两性霉素 B 脂质体 3mg/kg 而非 10mg/kg,以及阿比可尔、卡泊芬净和伏立康唑降低了脑 CFU。所有方案均降低了肾脏感染。两性霉素 B 脂质体或阿比可尔治疗可引起肾小管轻微变化,而心脏、肺和脑无药物毒性。两性霉素 B 的组织和血清浓度与疗效无关。感染过程中内皮细胞活化(脑毛细血管中的 ICAM-1 和 P-选择素)。来自两性霉素 B 脂质体和阿比可尔的两性霉素 B 定位于活化的内皮细胞中,来自阿比可尔的两性霉素 B 定位于血管内单核细胞中。在对未感染小鼠进行的 10 天研究中,阿比可尔或两性霉素 B 脂质体 1、5 或 10mg/kg 剂量加或不加环磷酰胺治疗后,可引起肾小管轻微变化;只有在用环磷酰胺治疗的小鼠中才出现阿比可尔引起的肾病。阿比可尔和两性霉素 B 脂质体均可引起肝毒性,但在环磷酰胺治疗的小鼠中肝毒性减轻。两性霉素 B 脂质体 3mg/kg 剂量可显著降低 CFU,与更强烈的炎症相关。阿比可尔的肾脏定位似乎是后期肾毒性的前兆。肝毒性可能导致高剂量阿比可尔和两性霉素 B 脂质体治疗失败。我们在感染期间观察到的内皮两性霉素定位是两性霉素疗效机制的新发现。

相似文献

1
Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Antimicrob Agents Chemother. 2012 Aug;56(8):4439-49. doi: 10.1128/AAC.06015-11. Epub 2012 Jun 11.
3
Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
J Antimicrob Chemother. 2006 Aug;58(2):466-9. doi: 10.1093/jac/dkl236. Epub 2006 Jun 7.
4
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Med Mycol. 2011 Nov;49(8):834-47. doi: 10.3109/13693786.2011.577822. Epub 2011 May 4.
6
Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
J Antimicrob Chemother. 2005 Jul;56(1):166-71. doi: 10.1093/jac/dki178. Epub 2005 May 25.
8
Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Antimicrob Agents Chemother. 2013 Jul;57(7):3046-59. doi: 10.1128/AAC.01660-12. Epub 2013 Apr 15.
10
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.
Int J Antimicrob Agents. 2006 Sep;28(3):262-5. doi: 10.1016/j.ijantimicag.2006.04.006.

引用本文的文献

2
Neuroimmune Responses in a New Experimental Animal Model of Cerebral Aspergillosis.
mBio. 2022 Oct 26;13(5):e0225422. doi: 10.1128/mbio.02254-22. Epub 2022 Aug 30.
3
Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis.
Microbiol Spectr. 2022 Jun 29;10(3):e0275321. doi: 10.1128/spectrum.02753-21. Epub 2022 Apr 18.
4
and aspergillosis: From basics to clinics.
Stud Mycol. 2021 May 10;100:100115. doi: 10.1016/j.simyco.2021.100115. eCollection 2021 Sep.
6
and Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.02673-18. Print 2019 Jun.
7
Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00489-18. Print 2018 Jul.
8
Animal Models of Aspergillosis.
Comp Med. 2018 Apr 2;68(2):109-123.
9
Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02009-17. Print 2018 Mar.
10
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00090-17. Print 2017 Jun.

本文引用的文献

1
Polyene macrolide antifungal drugs trigger interleukin-1β secretion by activating the NLRP3 inflammasome.
PLoS One. 2011;6(5):e19588. doi: 10.1371/journal.pone.0019588. Epub 2011 May 23.
2
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Med Mycol. 2011 Nov;49(8):834-47. doi: 10.3109/13693786.2011.577822. Epub 2011 May 4.
5
Immune cell entry to central nervous system--current understanding and prospective therapeutic targets.
Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):315-27. doi: 10.2174/187153009789839219.
6
Amphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in mice.
Hum Exp Toxicol. 2009 May;28(5):293-300. doi: 10.1177/0960327109105404. Epub 2009 Aug 6.
7
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation.
J Antimicrob Chemother. 2009 Jul;64(1):101-8. doi: 10.1093/jac/dkp140. Epub 2009 Apr 27.
9
Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data.
Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S125-31. doi: 10.1016/S0924-8579(08)70013-X.
10
Injury of the blood brain barrier and up-regulation of icam-1 in polymicrobial sepsis.
J Surg Res. 2008 May 15;146(2):276-81. doi: 10.1016/j.jss.2007.07.021. Epub 2007 Aug 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验